Drugs / Crolibulin
Crolibulin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00423410 | Dec 2006 → Apr 2009 | — | EpiCept Corporation | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01240590 | Jan 2011 → Aug 2015 | thyroid gland undifferentiated (anaplastic) carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Crolibulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01240590 ↗ |
| Known as | crinobulin | “EPC2407 (crinobulin)” NCT00423410 ↗ |
| Known as | Crolibulina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103852 ↗ |
| Known as | Crolibuline | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103852 ↗ |
| Known as | EPC2407 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00423410 ↗ |
| Action | Inhibit | “Microtubule Inhibitor” NCT00423410 ↗ |
| Modality | Small molecule | — CHEMBL2103852 ↗ |
| Route | Intravenous | “IV infusion 1 to 4 hours” NCT00423410 ↗ |